Merigolix

Merigolix
Clinical data
Other namesHS-10518; NCE-403; SKI-2670; TU-2670
Routes of
administration		Oral
Drug classGnRH antagonist
Identifiers
  • 4-[[(1R)-2-[1-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-2,4-dioxo-1'-[[5-(trifluoromethyl)furan-2-yl]methyl]spiro[7H-furo[3,4-d]pyrimidine-5,4'-piperidine]-3-yl]-1-phenylethyl]amino]butanoic acid
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC36H35F7N4O6
Molar mass752.687 g·mol−1
3D model (JSmol)
  • C1CN(CCC12C3=C(CO2)N(C(=O)N(C3=O)C[C@@H](C4=CC=CC=C4)NCCCC(=O)O)CC5=C(C=CC=C5F)C(F)(F)F)CC6=CC=C(O6)C(F)(F)F
  • InChI=1S/C36H35F7N4O6/c37-26-9-4-8-25(35(38,39)40)24(26)19-46-28-21-52-34(13-16-45(17-14-34)18-23-11-12-29(53-23)36(41,42)43)31(28)32(50)47(33(46)51)20-27(22-6-2-1-3-7-22)44-15-5-10-30(48)49/h1-4,6-9,11-12,27,44H,5,10,13-21H2,(H,48,49)/t27-/m0/s1
  • Key:LJPSGSMPGVITHK-MHZLTWQESA-N

Merigolix (INNTooltip International Nonproprietary Name; developmental code names HS-10518, NCE-403, SKI-2670, TU-2670) is a gonadotropin releasing hormone (GnRH) antagonist which is under development for the treatment of endometriosis and uterine fibroids. It is taken by mouth. The drug is being developed by TiumBio, Daewon Pharmaceutical, and Jiangsu Hansoh Pharmaceutical. As of October 2024, it is in phase 2 clinical trials for both endometriosis and uterine fibroids.

See also

References

  1. 1 2 3 4 5 "Merigolix". AdisInsight. 28 October 2024. Retrieved 24 February 2025.
  2. 1 2 3 "Delving into the Latest Updates on Merigolix with Synapse". Synapse. 22 February 2025. Retrieved 24 February 2025.
  3. ↑ Tukun FL, Olberg DE, Riss PJ, Haraldsen I, Kaass A, Klaveness J (December 2017). "Recent Development of Non-Peptide GnRH Antagonists". Molecules. 22 (12): 2188. doi:10.3390/molecules22122188. PMC 6149776. PMID 29232843.
  4. ↑ Farris M, Bastianelli C, Rosato E, Brosens I, Benagiano G (2019). "Uterine fibroids: an update on current and emerging medical treatment options". Therapeutics and Clinical Risk Management. 15: 157–178. doi:10.2147/TCRM.S147318. PMC 6350833. PMID 30774352.
  5. ↑ Angioni S, D'Alterio MN, Daniilidis A (2021). "Highlights on Medical Treatment of Uterine Fibroids". Current Pharmaceutical Design. 27 (36): 3821–3832. doi:10.2174/1381612826666210101152820. PMID 33388011.